Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04991571 · ClinicalTrials.gov registry record · Phase 1
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04991571 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 27 participants.
The verdict
NCT04991571, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan. Part 2 of the study is designed to evaluate the relative bioavailability of zibotentan and dapagliflozin after dosing with two different fixed-dose combination (FDC) formulations and dosing with separate formulations of zibotentan and dapagliflozin.
Interventions
- DRUG Zibotentan (Treatment A)
- DRUG Dapagliflozin (Treatment A)
- DRUG Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
- DRUG Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-07-29 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04991571
The ClinicalTrials.gov registry entry for NCT04991571 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zibotentan (Treatment A) is the first listed.
NCT04991571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04991571 about?
NCT04991571 is a clinical study titled "Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants". The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan. Part 2 of the study is designed to evaluate the relative bioavailability of zibotentan and dapaglifloz...
What is the current status of trial NCT04991571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-07-29. Estimated completion is 2021-10-22.
What interventions are being tested in trial NCT04991571?
The interventions under investigation include: Zibotentan (Treatment A) (DRUG), Dapagliflozin (Treatment A) (DRUG), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B) (DRUG), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C) (DRUG).
Who is sponsoring clinical trial NCT04991571?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.